AI reads brain scans to predict tumor survival before surgery
NCT ID NCT05864976
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study explores whether a computer algorithm can analyze resting-state MRI scans taken before surgery to predict how long a person with glioblastoma multiforme (a type of brain cancer) might survive. The goal is to see if the algorithm can accurately classify patients as short-term or long-term survivors, which could help guide treatment decisions. The study involves 100 adults with suspected glioblastoma who are scheduled for surgery and a pre-operative MRI.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Support Vector Machine (machine learning algorithm)
- What this could lead to
- If successful, this approach could help surgeons better plan brain tumor surgeries by identifying which patients may need more aggressive treatment.
- What could go wrong
- This is an early-stage study with only 100 participants, and the algorithm's predictions may not be accurate enough to change clinical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2023
- Expected to finish
-
Jan 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Participants being seen at Washington University School of Medicine.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Must have a radiological diagnosis of a lesion in the brain with characteristics consistent with glioblastoma multiforme. * Must be planning to undergo a pre-operative MRI. * Must be at least 18 years old. * Must be able to understand and willing to sign an IRB approved written informed consent document. Exclusion Criteria: * Contraindication to MRI. * Inability to have clinical follow-up (e.g., patient is out of town and will do follow-up elsewhere).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Glioblastoma multiforme are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug targets Sugar-Coated proteins on cancer cells
- Off-the-Shelf immune cells target solid tumors
- Could a parasite drug fight childhood brain tumors?
- Can mapping the Blood-Brain barrier in brain tumors unlock new clues?
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Brain cancer vaccine targets survivin protein to boost immune attack